Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Exagen (XGN) over the last 2 years, with Q3 2025 value amounting to $641000.0.

  • Exagen's Current Deferred Revenue changed N/A to $641000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $641000.0, marking a year-over-year change of. This contributed to the annual value of $733000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Exagen's Current Deferred Revenue stood at $641000.0.
  • In the past 5 years, Exagen's Current Deferred Revenue ranged from a high of $1.0 million in Q2 2025 and a low of $641000.0 during Q3 2025